The unique benefits of using empagliflozin need to be considered when determining treatments for type 2 patients.
Read More »Sotagliflozin: Implications in Patients Living With Chronic Kidney Disease
A new phase 3 study on novel SGLT inhibitor shows favorable results in those living with severe renal impairment.
Read More »Role of Magnesium in Type 2 Diabetes and Stroke
Adequate amounts of magnesium in the diet could reduce the risk of type 2 and cerebral vascular incidents.
Read More »Prolonged Use of Proton Pump Inhibitors Linked to Increased Risk of T2DM
Long-term users of the acid reflux drugs known as Proton Pump Inhibitors (PPIs) have a 24% higher risk of developing type 2 diabetes than non-PPI users.
Read More »The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »Telehealth, Smartphones, Mobile Apps and CGM: Changing The Way We Control Type 2 Diabetes In Adults
Can a virtual diabetes clinic (VDC) improve diabetes care?
Read More »Do DPP-4 Inhibitors Increase Risk of Pneumonia in Patients with T2D?
Since DPP-4 plays a role in infection for some coronaviruses, there is increased interest in whether patients using DPP-4 inhibitors are at greater pneumonia risk.
Read More »Part 3: Innovative Artificial Intelligence (AI) Tool Optimizes Care for T2D Patients
Optimize Clinical Diabetes Management with AI Technology
A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs.
In part 3: user testimonials about the experience and exciting findings using the software. A more in-depth examination of the benefits of applying decision-support software in clinical practice.
Part 2: Innovative Artificial Intelligence (AI) Tool Optimizes Care for T2D Patients
Collaborative Analysis Concludes that the AI Tool Improves Outcomes for Type 2 Diabetes Patients
A new clinical software using artificial intelligence is being used for those with Type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature is a 3-part series.
The project was designed to address through clinical intervention the issues experienced by patients with diabetes, such as high A1c levels. Through team-based care, clinical software support, and patient engagement, the intervention was projected to help control HbA1c and potentially lower treatment costs.
Innovative Artificial Intelligence (AI) Tool Optimizes Care for T2D Patients
A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature will be a 3-part series.
In Part 1: Adherence-related issues are hemorrhaging the costs of diabetes-related treatment in America. To offset this tragedy, GlucosePATH is utilized by a team of healthcare professionals dedicated to improving the quality of life while decreasing avoidable costs.